Demographic characteristics of study participants.
In this study, 405 and 135 subjects were enrolled in the QIV (Batch A, B and C) and TIV groups, respectively. Of the 405 subjects in the QIV group, three were excluded from immunogenicity analysis because of protocol non-compliance (